STOCK TITAN

Lifshitz Law PLLC Announces Investigations of SLGC, ORTX, SP

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags
Rhea-AI Summary
Lifshitz Law PLLC announces investigations of SLGC, ORTX, SP
Positive
  • SLGC shareholders to receive 1.11 shares of Standard BioTools for each share of SLGC owned
  • ORTX to be sold to Kyowa Kirin Co., Ltd. for $16.00 per ADS plus $1.00 per ADS
  • SP to be sold to Metropolis Technologies, Inc. for $54.00 per share in cash
Negative
  • None.

NEW YORK, October 7, 2023, 2023 / ACCESSWIRE /

SomaLogic, Inc. (NASDAQ:SLGC)

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of SLGC and Standard BioTools, Inc. Under the terms of the proposed transaction, SLGC shareholders will receive 1.11 shares of Standard BioTools, Inc. for each share of SLGC common stocked owned.

If you are a SLGC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Orchard Therapeutics PLC. (NASDAQ:ORTX)

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ORTX to Kyowa Kirin Co., Ltd. for $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS.

If you are an ORTX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

SP Plus Corporation (NASDAQ:SP)

Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SP to Metropolis Technologies, Inc. for $54.00 per share in cash.

If you are a SP investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

ATTORNEY ADVERTISING.© 2023 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: info@lifshitzlaw.com

SOURCE: Lifshitz Law PLLC



View source version on accesswire.com:
https://www.accesswire.com/790575/lifshitz-law-pllc-announces-investigations-of-slgc-ortx-sp

FAQ

What is the investigation about?

The investigation is about possible breach of fiduciary duties in the mergers and sales of SLGC, ORTX, and SP.

What will SLGC shareholders receive in the merger?

SLGC shareholders will receive 1.11 shares of Standard BioTools for each share of SLGC owned.

What is the sale price for ORTX?

ORTX will be sold for $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS.

What is the sale price for SP?

SP will be sold for $54.00 per share in cash.

How can I get additional information about the investigation?

To get additional information, complete the Information Request Form or contact Joshua Lifshitz, Esq. at (516)493-9780 or info@lifshitzlaw.com.

SomaLogic, Inc.

NASDAQ:SLGC

SLGC Rankings

SLGC Latest News

SLGC Stock Data

396.23M
153.26M
2.16%
61.71%
3.79%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
US
Boulder

About SLGC

revolutionizing proteomics to transform healthcare somalogic was founded in 2000 with the goal of improving the well-being and quality of life of every individual by transforming how diseases were detected and diagnosed. building on the previous decade of aptamer research, somalogic scientists have developed a new proteomics technology that overcomes the significant challenges of current technologies, and which has multiple applications across the biological and medical sciences. our mission is to leverage our proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare. if you would like to learn more about somalogic, contact us at information@somalogic.com or 303-625-9000